Skip to main content
GMEDGlobus Medical, Inc.Hold7.2·$82.36+5.19%
Open full analysis

Globus Medical, Inc. (GMED) Stock Analysis

Range Bound setup

HoldVALUE-TRAP 1/5Moderate Confidence

Healthcare · Medical Devices

Hold if already holding. Not a fresh buy at $82.36, but acceptable to hold if already in. Reason: Leverage penalty (D/E 2.5): -1.5.

Globus Medical is a musculoskeletal solutions company designing and selling spine, trauma, and enabling technology products — including surgical robots (ExcelsiusGPS) — to hospitals and surgical facilities globally. It earns revenue through direct and distributor-based device... Read more

$82.36+16.0% A.UpsideScore 7.2/10#1 of 40 Medical Devices
QualityF-score8 / 9FCF yield3.21%
Stop $77.48Target $95.70(analyst − 13%)A.R:R 1.6:1
Analyst target$110.00+33.6%11 analysts
$95.70our TP
$82.36price
$110.00mean
$122

Hold if already holding. Not a fresh buy at $82.36, but acceptable to hold if already in. Reason: Leverage penalty (D/E 2.5): -1.5. Chart setup: RSI 56 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 7.2/10, moderate confidence.

Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Aug 6, 202658d to earnings· next earnings call

Thesis

Rewards
V7 quality resilience bonus: +0.2 (Q=7.2 in RISK_OFF)
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Risks
Leverage penalty (D/E 2.5): -1.5

Key Metrics

P/E (TTM)18.3
P/E (Fwd)15.2
Mkt Cap$10.6B
EV/EBITDA10.7
Profit Mgn18.9%
ROE13.3%
Rev Growth27.0%
Beta0.95
DividendNone
Rating analysts21

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C0.75neutral
IV56%elevated
Max Pain$33-60.5% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 ceiling hit

GatesMomentum 6.5>=5.5A.R:R 1.6 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 58d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Moderate
RSI
56 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $74.50Resistance $86.02

Price Targets

$77
$96
A.Upside+16.2%
A.R:R1.6:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Analyst Consensus

Analysts21
Consensus3.9/5
Avg Target$110

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-06 (58d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is GMED stock a buy right now?

Hold if already holding. Not a fresh buy at $82.36, but acceptable to hold if already in. Reason: Leverage penalty (D/E 2.5): -1.5. Chart setup: RSI 56 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $95.70 (+16.2%), stop $77.48 (−6.3%), A.R:R 1.6:1. Score 7.2/10, moderate confidence.

What is the GMED stock price target?

Take-profit target: $95.70 (+16.0% upside). Target $95.70 (+16.2%), stop $77.48 (−6.3%), A.R:R 1.6:1. Stop-loss: $77.48.

What are the risks of investing in GMED?

Leverage penalty (D/E 2.5): -1.5.

Is GMED overvalued or undervalued?

Globus Medical, Inc. trades at a P/E of 18.3 (forward 15.2). TrendMatrix value score: 7.8/10. Verdict: Hold.

What do analysts say about GMED?

21 analysts cover GMED with a consensus score of 3.9/5. Average price target: $110.

What does Globus Medical, Inc. do?Globus Medical is a musculoskeletal solutions company designing and selling spine, trauma, and enabling technology...

Globus Medical is a musculoskeletal solutions company designing and selling spine, trauma, and enabling technology products — including surgical robots (ExcelsiusGPS) — to hospitals and surgical facilities globally. It earns revenue through direct and distributor-based device sales, with approximately 80% from the U.S. market following its 2023 NuVasive merger.

Related stocks: PODD (Insulet Corporation) · BSX (Boston Scientific Corporation) · DXCM (DexCom, Inc.) · ATEC (Alphatec Holdings, Inc.) · SNN (Smith & Nephew SNATS, Inc.)
Home Stocks GMED

Latest news

Latest News

Newser47d agoMerger Acquisition
MSN34d ago
MSN40d agoEarnings
Yahoo Finance40d agoAnalyst
StockStory41d agoEarnings
GuruFocus48d ago
Yahoo Finance49d agoEarnings
The Globe and Mail35d agoAnalyst
Insider Monkey46d ago
Yahoo Finance46d agoEarnings
Yahoo Finance39d agoEarnings
Quiver Quantitative39d ago
StockStory39d ago
TradingView39d ago
Marketscreener.com39d agoEarnings
Marketscreener.com39d agoEarnings
Newser40d ago
TradingView36d agoEarnings
Simplywall.st36d ago
MarketBeat43d ago
Loading more...